cas 2555-05-7|| where to buy 3-Methylpyrrolidin-2-one

Nom du produit:3-Methylpyrrolidin-2-one

IUPAC Name:3-methylpyrrolidin-2-one

Unité d'emballage	Stock disponible	Prix($)
CM196917-100mg	in stock	ȡƃ
CM196917-250mg	in stock	ƃƃǑ
CM196917-1g	in stock	ƥȡƥ
CM196917-5g	in stock	ũƃƥ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2555-05-7 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:2555-05-7; Formule moléculaire:C5H9NO; Point de fusion:-; Code SMILES:CC1CCNC1=O; Densité:

: Numéro de catalogue:CM196917; Poids moléculaire:99.13; Point d'ébullition:240.5°C at 760 mmHg; N° Mdl:MFCD00005271; Stockage:Store at room temperature.

: Pyrrolidines; Pyrrolidine, also known as tetrahydropyrrole, is a saturated five-membered heterocyclic ring, which is miscible with water. Pyrrolidine exists in many alkaloids and drug molecules, such as kappa opioids, antagonists of dopamine D4 receptors, and HIV reverse transcriptase inhibitors.

: Buntanetap; Alzheimer's disease (AD) is the most common neurodegenerative disorder worldwide. As the world ages, the demand for Alzheimer's disease (AD) drugs increases dramatically. Alzheimer's disease (AD) will also continue to be an industry focus in 2024. There are various types of AD drugs, including vaccines, monoclonal antibodies, and small molecule inhibitors. Lecanemab has become the first new AD treatment to be fully approved by the FDA in 20 years. Lilly's AD treatment donanemab is under review by the FDA. Among small molecule drugs, buntanetap is a a novel translational inhibitor developed by Annovis. Buntanetap reduces levels of multiple neurotoxic proteins (beta amyloid, tau, alpha synuclein, and TDP43), thereby improving synaptic transmission and axonal transport and reducing inflammation, which has been shown to be a cause of cell death reason. By attacking multiple pathways associated with neurodegeneration, buntanetap can reverse Alzheimer's disease's devastating effects on thinking and memory.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.